14,025.25
-595.80
(-4.07%)
At close: January 10 at 3:29:38 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
14,853,661.00
15,156,631.00
11,608,985.00
9,233,341.00
9,181,767.00
Cost of Revenue
7,314,045.00
7,337,967.00
6,137,853.00
5,535,020.00
5,547,189.00
Gross Profit
7,539,616.00
7,818,664.00
5,471,132.00
3,698,321.00
3,634,578.00
Operating Expense
3,996,601.00
3,744,842.00
3,127,718.00
2,737,418.00
2,538,244.00
Operating Income
3,543,015.00
4,073,822.00
2,343,414.00
960,903.00
1,096,334.00
Net Non Operating Interest Income Expense
-28,571.00
-57,706.00
-115,108.00
-124,994.00
-162,308.00
Pretax Income
3,759,476.00
4,014,365.00
2,157,464.00
821,625.00
1,053,336.00
Tax Provision
962,801.00
1,013,576.00
522,288.00
183,405.00
247,028.00
Net Income Common Stockholders
2,796,675.00
3,000,789.00
1,635,176.00
638,220.00
806,307.00
Diluted NI Available to Com Stockholders
2,796,675.00
3,000,789.00
1,635,176.00
638,220.00
806,307.00
Basic EPS
217.98
233.89
127.45
49.74
62.85
Diluted EPS
217.98
233.89
127.45
49.74
62.85
Basic Average Shares
12,829.96
12,829.89
12,829.89
12,829.89
12,829.89
Diluted Average Shares
12,829.96
12,829.89
12,829.89
12,829.89
12,829.89
Rent Expense Supplemental
--
9,202.00
8,381.00
7,132.00
7,142.00
Total Expenses
11,310,646.00
11,082,809.00
9,265,571.00
8,272,438.00
8,085,433.00
Net Income from Continuing & Discontinued Operation
2,796,675.00
3,000,789.00
1,635,176.00
638,220.00
806,307.00
Normalized Income
2,644,133.05
3,001,685.27
1,614,498.54
652,264.92
808,399.82
Interest Income
--
82,268.00
15,563.00
9,950.00
16,675.00
Interest Expense
81,609.00
110,744.00
104,015.00
95,335.00
128,005.00
Net Interest Income
-28,571.00
-57,706.00
-115,108.00
-124,994.00
-162,308.00
EBIT
3,841,085.00
4,125,109.00
2,261,479.00
916,960.00
1,181,341.00
EBITDA
4,480,693.00
4,722,108.00
2,789,253.00
1,407,362.00
1,578,166.00
Reconciled Cost of Revenue
7,314,045.00
7,337,967.00
6,137,853.00
5,535,020.00
5,547,189.00
Reconciled Depreciation
639,608.00
596,999.00
527,774.00
490,402.00
396,825.00
Net Income from Continuing Operation Net Minority Interest
2,796,675.00
3,000,789.00
1,635,176.00
638,220.00
806,307.00
Total Unusual Items Excluding Goodwill
205,057.00
-1,199.00
27,282.00
-18,081.00
-2,734.00
Total Unusual Items
205,057.00
-1,199.00
27,282.00
-18,081.00
-2,734.00
Normalized EBITDA
4,275,636.00
4,723,307.00
2,761,971.00
1,425,443.00
1,580,900.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
52,515.05
-302.73
6,604.54
-4,036.08
-641.18
3/31/2021 - 12/18/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AARTIPHARM.BO Aarti Pharmalabs Limited
669.05
+1.53%
APLLTD.BO Alembic Pharmaceuticals Limited
1,008.95
-4.36%
SOLARA.BO Solara Active Pharma Sciences Limited
655.15
-3.89%
ORCHPHARMA.BO Orchid Pharma Limited
1,845.95
-2.06%
FDC.NS FDC Limited
488.55
-0.06%
BAJAJHCARE.BO Bajaj HealthCare Limited
536.95
-1.53%
SEQUENT.BO Sequent Scientific Limited
177.95
-4.58%
JAGSNPHARM.BO Jagsonpal Pharmaceuticals Limited
214.00
-7.74%
HIKAL.NS Hikal Limited
358.05
-3.66%
JBCHEPHARM.NS J. B. Chemicals & Pharmaceuticals Limited
1,823.05
-2.53%